Published in Eur J Cancer on March 01, 2004
Complementary and alternative medicine use in oncology: a questionnaire survey of patients and health care professionals. BMC Cancer (2011) 1.16
The use of Complementary and Alternative Medicine by cancer patients. Int Semin Surg Oncol (2007) 0.95
Is a biopsychosocial-spiritual approach relevant to cancer treatment? A study of patients and oncology staff members on issues of complementary medicine and spirituality. Support Care Cancer (2005) 0.92
Herbal medicine and acupuncture for breast cancer palliative care and adjuvant therapy. Evid Based Complement Alternat Med (2013) 0.90
Traditional complementary and alternative medicine: knowledge, attitudes and practices of health care workers in HIV and AIDS clinics in Durban hospitals. Afr J Tradit Complement Altern Med (2012) 0.87
Discrepant views of Korean medical oncologists and cancer patients on complementary and alternative medicine. Cancer Res Treat (2008) 0.86
Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. Support Care Cancer (2008) 0.85
Knowledge about complementary, alternative and integrative medicine (CAM) among registered health care providers in Swedish surgical care: a national survey among university hospitals. BMC Complement Altern Med (2012) 0.84
Patients in Northwestern Turkey Prefer Herbs as Complementary Medicine after Breast Cancer Diagnosis. Breast Care (Basel) (2008) 0.80
Experiences of complementary and alternative medicine in patients with inflammatory bowel disease - a qualitative study. BMC Complement Altern Med (2014) 0.79
Cancer and complementary medicine: an international perspective. Support Care Cancer (2007) 0.78
Complementary Medicine Health Literacy among a Population of Older Australians Living in Retirement Villages: A Mixed Methods Study. Evid Based Complement Alternat Med (2016) 0.78
National survey of China's oncologists' knowledge, attitudes, and clinical practice patterns on complementary and alternative medicine. Oncotarget (2017) 0.75
Mapping the risk perception and communication gap between different professions of healthcare providers in cancer care: a cross-sectional protocol. BMJ Open (2015) 0.75
Complementary and conventional providers in cancer care: experience of communication with patients and steps to improve communication with other providers. BMC Complement Altern Med (2017) 0.75
Gynecologic oncologists' attitudes and practices relating to integrative medicine: results of a nationwide AGO survey. Arch Gynecol Obstet (2017) 0.75
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Information and participation preferences among cancer patients. Ann Intern Med (1980) 11.05
Informed consent -- why are its goals imperfectly realized? N Engl J Med (1980) 6.43
The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer (1998) 4.95
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet (1995) 3.03
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Diagnostic delay causes more psychological distress in female than in male cancer patients. Anticancer Res (1996) 2.62
Attitudes toward clinical trials among patients and the public. JAMA (1982) 2.53
Episiotomy characteristics and risks for obstetric anal sphincter injuries: a case-control study. BJOG (2012) 2.41
Psychosocial status in chronic illness. A comparative analysis of six diagnostic groups. N Engl J Med (1984) 2.24
Symptom prevalence and control during cancer patients' last days of life. J Palliat Care (1990) 2.22
Cancer patients use of nonproven therapy: a 5-year follow-up study. J Clin Oncol (1998) 2.05
Breast cancer surveillance: on increasing its effectiveness while reducing its negative psychological effects. J Natl Cancer Inst (1992) 2.04
[Treatment with growth factors and cytokines in hematologic diseases]. Tidsskr Nor Laegeforen (1996) 2.03
Contemporary unorthodox treatments in cancer medicine. A study of patients, treatments, and practitioners. Ann Intern Med (1984) 2.03
Epidemiology of blindness in Nepal. Bull World Health Organ (1985) 1.91
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat (2001) 1.88
Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol (2006) 1.85
Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer (1995) 1.78
Some environmental and bodily characteristics of melanoma patients. A case-control study. Int J Cancer (1979) 1.76
Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology (2003) 1.72
Mean platelet volume is a risk factor for venous thromboembolism: the Tromsø Study, Tromsø, Norway. J Thromb Haemost (2009) 1.72
Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant (2001) 1.66
Does use of alternative medicine predict survival from cancer? Eur J Cancer (2003) 1.62
The level of physical activity in long-term survivors of testicular cancer. Eur J Cancer (2003) 1.61
Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer (2001) 1.50
Proton nuclear magnetic resonance spectroscopy of plasma from healthy subjects and patients with cancer. N Engl J Med (1990) 1.48
Psychosocial correlates of survival in advanced malignant disease? N Engl J Med (1985) 1.48
Associations among cataract prevalence, sunlight hours, and altitude in the Himalayas. Am J Epidemiol (1983) 1.47
Clinical stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution. Ann Oncol (1996) 1.45
Persistent changes in the immune system 4-10 years after ABMT. Bone Marrow Transplant (1999) 1.44
Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol (2007) 1.41
Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol (1991) 1.39
Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. 1996. Int J Hyperthermia (2009) 1.39
[High-dose autologous stem cell support in malignant diseases--an established method, uncertain indication]. Tidsskr Nor Laegeforen (1994) 1.39
Stress and the development of breast cancer: a persistent and popular link despite contrary evidence. Cancer (1996) 1.37
Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol (2002) 1.37
How well do physicians recognize melanoma and other problem lesions? J Am Acad Dermatol (1986) 1.34
CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989-2003. AJNR Am J Neuroradiol (2009) 1.30
Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer (2000) 1.29
Increase in weight in all birth cohorts in a general population: The Tromsø Study, 1974-1994. Arch Intern Med (2001) 1.29
Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Tromsø study. J Thromb Haemost (2008) 1.25
Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia (1996) 1.18
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol (2008) 1.17
A psychological analysis of cancer patients and their next-of-kin. Cancer (1985) 1.17
Program evaluation in terminal care. Hosp J (1985) 1.15
A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation. Bone Marrow Transplant (2004) 1.14
Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromsø study. J Thromb Haemost (2008) 1.13
The risk of spontaneous pneumothorax in patients with osteogenic sarcoma and testicular cancer. Cancer (1982) 1.12
Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol (2005) 1.09
Incidence and mortality of aneurysmal subarachnoid hemorrhage in two Norwegian cohorts, 1984-2007. Neurology (2011) 1.08
Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation. Eur J Immunol (1990) 1.08
How useful are unconventional cancer treatments? Eur J Cancer (1999) 1.07
Walking after stroke: does it matter? Changes in bone mineral density within the first 12 months after stroke. A longitudinal study. Osteoporos Int (2000) 1.07
Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. Br J Cancer (2009) 1.06
Chromosome analyses of nurses handling cytostatic agents. Cancer Treat Rep (1981) 1.04
Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes. Exp Cell Res (1987) 1.02
Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol (2002) 1.02
Association of Kaposi's sarcoma and prior immunosuppressive therapy: a 5-year material of Kaposi's sarcoma in Norway. Cancer (1978) 1.02
A phase II study of oral VP-16-213 in non-seminomatous testicular cancer. Eur J Cancer (1981) 1.00
Impact of cardiovascular risk factors on cognitive function: the Tromsø study. Eur J Neurol (2010) 1.00
Patients' perceptions of the cosmetic impact of melanoma resection. Plast Reconstr Surg (1983) 1.00
Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study. J Thromb Haemost (2011) 0.99
Unconventional therapies for cancer and cancer-related symptoms. Lancet Oncol (2001) 0.99
Relationship between patients' early recognition of melanoma and depth of invasion. Cancer (1982) 0.98
Increased growth rate of abdominal aortic aneurysms in women. The Tromsø study. Eur J Vasc Endovasc Surg (2005) 0.97
Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol (2013) 0.96
A pilot study of the Functional Living Index-Cancer (FLIC) Scale for the assessment of quality of life for metastatic lung cancer patients. An Eastern Cooperative Oncology Group study. Am J Clin Oncol (1988) 0.96
Post-treatment parenthood in Hodgkin's lymphoma survivors. Br J Cancer (2007) 0.94
Moderate wine consumption is associated with better cognitive test results: a 7 year follow up of 5033 subjects in the Tromsø Study. Acta Neurol Scand Suppl (2010) 0.94
Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology (Oxford) (2001) 0.93
Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol (2004) 0.93
Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol (2007) 0.93
Glioma cell interactions with fetal rat brain aggregates in vitro and with brain tissue in vivo. Cancer Res (1986) 0.92
The effect of experience on radiation therapy patients' desire for information. Int J Radiat Oncol Biol Phys (1980) 0.90
Reference ranges for serial measurements of blood velocity and pulsatility index at the intra-abdominal portion, and fetal and placental ends of the umbilical artery. Ultrasound Obstet Gynecol (2005) 0.90
Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma. Int J Cancer (2000) 0.89
Opinions on and use of alternative medicine among physicians, nurses and clerks in northern Norway. In Vivo (2000) 0.89
Relation between serum osteoprotegerin and carotid intima media thickness in a general population - the Tromsø Study. J Thromb Haemost (2010) 0.89
Hodgkin's disease in a national and hospital population: trends over 20 years. Eur J Cancer (1997) 0.89
Prognosis for chronic obstructive pulmonary disease patients who receive long-term oxygen therapy. Int J Tuberc Lung Dis (1999) 0.88
Gene variations in sex hormone pathways and the risk of testicular germ cell tumour: a case-parent triad study in a Norwegian-Swedish population. Hum Reprod (2012) 0.88
Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population--the Tromsø study. J Thromb Haemost (2010) 0.88
Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year? Bone Marrow Transplant (1999) 0.88
Doppler-derived umbilical artery absolute velocities and their relationship to fetoplacental volume blood flow: a longitudinal study. Ultrasound Obstet Gynecol (2005) 0.88
Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol (1986) 0.87
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol (2007) 0.87